Neoadjuvant treatment with trastuzumab and pertuzumab plus fulvestrant in older patients with HER2-positive, ER-positive early breast cancer.

被引：0

作者：

Celis, Juan Jose ^{[1
]}

Rodriguez, Vanessa ^{[1
]}

Rodriguez, Crismar ^{[1
]}

机构：

[1] Soc Anticancerosa Venezuela, Caracas, Venezuela

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 23_SUPPL期

关键词：

D O I：

10.1200/JCO.2024.42.23_suppl.13

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：13 / 13

页数：1

共 50 条

[1] Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study
Gianni, Luca
Bisagni, Giancarlo
Colleoni, Marco
Del Mastro, Lucia
Zamagni, Claudio
Mansutti, Mauro
Zambetti, Milvia
Frassoldati, Antonio
De Fato, Raffaella
Valagussa, Pinuccia
Viale, Giuseppe
LANCET ONCOLOGY, 2018, 19 (02): : 249 - 256
[2] Pertuzumab in neoadjuvant treatment of HER2-positive early breast cancer
Abraham, Jame
JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2014, 12 (03): : 84 - 86
[3] Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
Vieira, Claudia
Borges, Andreia
Pereira, Filipa F.
Antunes, Pedro
Redondo, Patricia
Antunes, Luis
Lopes, Jose M.
Goncalves, Francisco R.
Borges, Marina
Bento, Maria J.
JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2023, 6 (01) : 1 - 9
[4] Pertuzumab plus trastuzumab increases survival in patients with HER2-positive breast cancer
Mayor, Susan
BRITISH JOURNAL OF HOSPITAL MEDICINE, 2014, 75 (11) : 611 - 611
[5] Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
Douchet, G.
Richard, Sandrine
ONCOLOGIE, 2018, 20 (01) : 43 - 44
[6] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
von Minckwitz, Gunter
Procter, Marion
de Azambuja, Evandro
Zardavas, Dimitrios
Benyunes, Mark
Viale, Giuseppe
Suter, Thomas
Arahmani, Amal
Rouchet, Nathalie
Clark, Emma
Knott, Adam
Lang, Istvan
Levy, Christelle
Yardley, Denise A.
Bines, Jose
Gelber, Richard D.
Piccart, Martine
Baselga, Jose
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02): : 122 - 131
[7] Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience
Hall, Benjamin James
Bhojwani, Ajay Ashok
Wong, Helen
Law, Andrea
Flint, Helen
Ahmed, Eliyaz
Innes, Helen
Cliff, Joanne
Malik, Zaf
O'Hagan, Julie Elizabeth
Hall, Allison
Sripadam, Rajaram
Tolan, Shaun
Ali, Zulfiqar
Hart, Clare
Errington, Douglas
Alam, Farida
Giuliani, Rosa
Mehta, Shaveta
Khanduri, Sheena
Thorp, Nicky
Jackson, Richard
Cicconi, Silvia
Palmieri, Carlo
BREAST JOURNAL, 2022, 2022
[8] Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Bianchini, Giampaolo
Kiermaier, Astrid
Bianchi, Giulia Valeria
Im, Young-Hyuck
Pienkowski, Tadeusz
Liu, Mei-Ching
Tseng, Ling-Ming
Dowsett, Mitch
Zabaglo, Lila
Kirk, Sarah
Szado, Tania
Eng-Wong, Jennifer
Amler, Lukas C.
Valagussa, Pinuccia
Gianni, Luca
BREAST CANCER RESEARCH, 2017, 19
[9] Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Giampaolo Bianchini
Astrid Kiermaier
Giulia Valeria Bianchi
Young-Hyuck Im
Tadeusz Pienkowski
Mei-Ching Liu
Ling-Ming Tseng
Mitch Dowsett
Lila Zabaglo
Sarah Kirk
Tania Szado
Jennifer Eng-Wong
Lukas C. Amler
Pinuccia Valagussa
Luca Gianni
Breast Cancer Research, 19
[10] Complete response after "neoadjuvant" pertuzumab plus trastuzumab plus docetaxel chemotherapy in Her2-positive breast cancer
Lai-Tiong, F.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (05) : 836 - 837

← 1 2 3 4 5 →